)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Immix Biopharma (IMMX) investor relations material
Immix Biopharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary8 Aug, 2025
Executive summary
Focused on CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis, with ongoing Phase 1b/2 trials in the US and ex-US, and expansion to 18 clinical sites as of July 2025.
NXC-201 has received FDA RMAT and Orphan Drug Designation, as well as European ODD, and has shown high response rates in clinical data presented at major conferences.
Awarded an $8M CIRM grant to support NXC-201 clinical development, with $3.6M received and $4.4M remaining as of August 2025.
Company operates as a single segment, with all significant decisions made at the consolidated level.
Financial highlights
Cash and cash equivalents were $11.6M as of June 30, 2025, with $12M reported in a subsequent update.
Net loss for Q2 2025 was $6.6M, up from $4.4M in Q2 2024; net loss for the six months ended June 30, 2025 was $11.2M, up from $9.7M year-over-year.
General and administrative expenses for Q2 2025 were $2.7M (up from $2.5M), and R&D expenses were $4.0M (up from $2.2M) compared to Q2 2024.
Interest income declined to $104K in Q2 2025 from $307K in Q2 2024 due to lower cash balances.
Net cash used in operating activities for the six months ended June 30, 2025 was $7.0M, down from $9.1M in the prior year period.
Outlook and guidance
Management expects continued operating losses and insufficient capital to fund operations for the next twelve months, indicating substantial doubt about the ability to continue as a going concern.
Plans to seek additional capital through equity, debt, grants, or strategic partnerships; alternatives to the current business plan may be considered if funding is not secured.
Funding strategy for operations beyond Q3 2026?
Next steps for NXC-201 registrational trial?
Future financial commitments from license deals?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Immix Biopharma earnings date
Q3 202510 Nov, 2025
Next Immix Biopharma earnings date
Q3 202510 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Immix Biopharma Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for cancer and inflammatory diseases. The company’s lead programs are based on its proprietary tissue-specific therapeutics platform, designed to deliver biologics and small molecules to specific tissues while minimizing systemic toxicity. Immix Biopharma conducts clinical trials for rare and hard-to-treat cancers, as well as immune-related conditions. The company is headquartered in Los Angeles, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage